Biogen (BIIB) Equity Ratio (2009 - 2026)

Biogen's Equity Ratio history runs 18 years deep, the most recent figure standing at 0.63 for Q1 2026.

• In Q1 2026, Equity Ratio rose 4.45% year-over-year to 0.63; the TTM figure through Mar 2026 stood at 0.63 (up 4.45% YoY), while the FY2025 annual figure was 0.62, up 4.06% from the prior year.
• Equity Ratio was 0.63 for Q1 2026 at Biogen, up from 0.62 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.63 in Q1 2026 to a low of 0.0 in Q3 2025.
• Historically, Equity Ratio has averaged 0.53 across 5 years, with a median of 0.57 in 2024.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio grew 21.53% in 2023, then tumbled 99.69% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.55 in 2022, then rose by 1.11% to 0.55 in 2023, then rose by 8.1% to 0.6 in 2024, then gained by 4.06% to 0.62 in 2025, then increased by 2.01% to 0.63 in 2026.
• The last three Equity Ratio figures came in at 0.63 (Q1 2026), 0.62 (Q4 2025), and 0.0 (Q3 2025), per Business Quant data.